Recruiting
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
J2T-MC-KGAK - ClinicalTrials.gov - NCT04626297
The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).
How long will I be in the trial?
The study will last up to 32 weeks and may include up to 11 visits.
Recruiting
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
J2T-MC-KGAK - ClinicalTrials.gov - NCT04626297
The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).
How long will I be in the trial?
The study will last up to 32 weeks and may include up to 11 visits.
Key Requirements
Age :
18-55
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-55
Sex
All
Participants must
Participants must have chronic atopic dermatitis
Participants must have had unsatisfactory results with existing medications applied to the skin
Participants must NOT
Participants must not have a history of anaphalaxis (severe, life threatening allergic reaction)
Participants must not have certain types of infection
Participants must not have other skin conditions or diseases that would interfere with the study
Participants must not have a history of certain types of cancers
Participants must not be pregnant or breastfeeding
Participants must have not received any tetanus-containing vaccine within approximately 5 years of baseline
Participants must have never received a meningitis vaccine (MCV), or have received only 1 prior MCV at least 4 years prior to baseline
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
yes
Enrollment Goal
240
Trial Dates
November 2020 - January 2022
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18-55
Sex
All
Participants must
Participants must have chronic atopic dermatitis
Participants must have had unsatisfactory results with existing medications applied to the skin
Participants must NOT
Participants must not have a history of anaphalaxis (severe, life threatening allergic reaction)
Participants must not have certain types of infection
Participants must not have other skin conditions or diseases that would interfere with the study
Participants must not have a history of certain types of cancers
Participants must not be pregnant or breastfeeding
Participants must have not received any tetanus-containing vaccine within approximately 5 years of baseline
Participants must have never received a meningitis vaccine (MCV), or have received only 1 prior MCV at least 4 years prior to baseline
Trial Summary
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Lebrikizumab
Could I receive a Placebo?
yes
Enrollment Goal
240
Trial Dates
November 2020 - January 2022
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Atopic Dermatitis (Eczema) Resources
